The QARRUS™ Microparticle Platform is designed to ensure that chemotherapy reaches a tumor and supporting cells while keeping systemic drug levels well below toxicity limits.
An established tumor presents a robust biology where highly evolvable cancer stem cells synergize with anti-inflammatory macrophage cells to fuel growth and drive metastasis.
Clinical-stage attrition of new chemotherapeutics
Each year 30-40 chemotherapy drugs fail clinical trials. Almost all of them are administered as simple formulations, such as pills or intravenous solutions. The high annual attrition rates of these chemotherapeutics are often attributable to dose-related toxicity.
Off-target delivery carries hidden risks
Only a fraction of a percent of an intravenous (i.v.) chemotherapy reaches a tumor and impacts its growth.
Many of these issues only become apparent in clinical trials after significant investment in R&D and patents.
Systemic formulations offer only marginal improvement
Even simple improvements to a drug’s formulation can dramatically improve its pharmacological profile by targeting its delivery. Both passive and molecularly targeted formulations increase the amount of drug reaching tumors by 1-2 orders of magnitude over simple solutions. Yet these formulations still deliver the majority of their drug to healthy cells resulting in significant toxicity.
QR206 disperses into regional metastatic sites by targeting phagocytic cells, effectively “chasing down” undetectable, regional metastases
Qrono first demonstrated proof-of-concept for QARRUS™ in HNSCC xenografts using epothilone D (EpoD), a tubulin inhibitor that failed clinical trials. A single injection of QARRUS™-formulated EpoD (QR206) significantly outperformed an equivalent bolus of unformulated drug, reducing relative tumor volume 4‑fold over 4 weeks (T-test, *p < 0.04, ** p < 0.02) and maintained systemic exposure 5x below toxicity threshold.
QR206’s impact on tumor growth correlates directly with elevated drug levels in tumor and lymph nodes (DLN) relative to equal bolus dose. Data for 26 days post-injection (T-test, *p < 0.15, ** p < 0.09).
Contact Qrono today for an in depth introduction to the QARRUS platform.
We look forward to partnering on improved chemotherapeutics.